Discover 2,427 paid clinical trials in Bethesda, Maryland. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 2,427
Ketoconazole Effects on the Daily Cortisol Rhythm in Mild Autonomous Cortisol Secretion
for
Mild Autonomous Cortisol Secretion
Location: Bethesda MD
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sex: All
Age: 18 - 70+
Code: NCT07649317
Phase 1, Recruiting
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
for
Sickle Cell Disease, Hemolytic Anemia
Location: Bethesda MD
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sex: All
Age: 18 - 70+
Code: NCT07566494
Phase 1, Recruiting
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
for
Leukemia, Lymphoma, Hematologic Malignancy
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT06856226
Recruiting
Hepatic Lipid Metabolism-Alcohol Use Disorder
for
Alcohol Use Disorder
Location: Bethesda MD
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sex: All
Age: 18 - 70+
Code: NCT07191561
Recruiting
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sex: All
Age: 18 - 70
Code: NCT00001853
Recruiting
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
for
Eczema, Atopic Dermatitis
Location: Bethesda MD
Sponsor: National Human Genome Research Institute (NHGRI)
Sex: All
Age: 2 - 70+
Code: NCT00605878
Recruiting
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...